Neupath Health Inc. · TSXV:NPTH
Neupath Health — Investor Presentation (January 2025)
20 slides from Neupath Health's investor presentation, January 2025
Slide 1: Investor Update
Investor Update January 2025 Growing Canada’s Largest Network of Chronic Pain Treatment Facilities (All figures in C$ unless otherwise indicated)
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation are forward looking statements which may include, but are not limited to, statements with respect to the future financial or operating performance of NeuPath and its projects, the market conditions, business strategy, corporate plans
Slide 3: Non-IFRS Financial Measures
Non-IFRS Financial Measures This presentation makes reference to certain financial measures, including non-IFRS financial measures that are historical and non-GAAP or non-GAAP ratios. Management uses these financial measures for purposes of comparison to prior periods and development of future proje
Slide 4: Growing Canada’s Leader in Chronic Pain Treatment
Growing Canada’s Leader in Chronic Pain Treatment NeuPath (TSXV:NPTH) operates a growing network of chronic pain treatment facilities. We deliver cutting- edge multi-disciplinary care. Large need, growing market Multiple organic and inorganic growth opportunities Regulated medical facilities,
Slide 5: Delivering Excellence at Scale
Delivering Excellence at Scale Our patient-centred multidisciplinary care model involves a wide range of specialties, including physiatrists, neurologists, anaesthesiologists, orthopedic surgeons, general practitioners with specialized training, sports medicine, physiotherapists and other allied hea
Slide 6: Improving Financial Performance Enables Growth
Improving Financial Performance Enables Growth Revenue growing $70M annual revenue run rate (as of Sept 30, 2024) $17.6M and $53.9M for the 3 and 9 months ended Sept. Improving 30, 2024, up 9% vs. same periods in 2023 Capacity Ongoing expansion in existing and new markets is Utilization expect
Slide 7: Chronic Pain Impacts One in Five Canadians
Chronic Pain Impacts One in Five Canadians Spinal Injuries Chronic Pain Chronic Pain Costs up to $40 billion in Canada(1) Musculoskeletal Pain Leading cause of disability worldwide Musculoskeletal Conditions Biggest cost driver in organizations’ Sport healthcare spend in Canada Concussions Med
Slide 8: We Treat Patients with a Wide Range Drivers of Pain
We Treat Patients with a Wide Range Drivers of Pain NeuPath’s physicians cater to individuals who have trouble taking care of themselves or their family due to their condition Arthritis & Musculoskeletal Pain Fibromyalgia Rotator Cuff Injuries Back Pain Head & Neck Pain Scoliosis Cervical Radiculopa
Slide 9: Reaching Patients in High-Growth Regions
Reaching Patients in High-Growth Regions NeuPath operates the largest network for chronic pain facilities in Canada • Currently addressing ~67% and ~38% of Ontario and Alberta’s population, respectively • Planning expansion in existing and new high-growth regions across Canada Alberta Southern Ontar
Slide 10: Key Growth Driver: Attracting and Retaining Physicians
Key Growth Driver: Attracting and Retaining Physicians Regulated treatment facilities Access to new technologies, modern equipment Built in referral network to rapidly build practice HR, IT and administration handled by NeuPath Excellent working conditions Doctors want to focus on deliveri
Slide 11: Multiple Avenues for Growth
Multiple Avenues for Growth Well-positioned for organic and inorganic growth opportunities… 3. Expand Through Adjacent Markets 2. Expand Our Orthopedics & specialties Network with high overlapping 1. Increase Capacity patient cohorts Utilization in Existing Build-out a pan-Canadian Facilities na
Slide 12: Favorable Macro Environment
Favorable Macro Environment Rising demand for services (lifestyle, aging population) Growing number of sophisticated medical procedures for alleviation of chronic pain Governments targeting more community-based care Public priority to limit use of opioids(1) Favorable lease terms for comme
Slide 13: Growing Revenue, Rapidly Growing Cashflow
Growing Revenue, Rapidly Growing Cashflow 7% 51% CAGR CAGR $80 120.0% $3.7 $70.7 $70 $65.4 $3.2 $62.2 100.0% $60 Ongoing Growth of $2.5 $50 expansion in 80.0% Adj EBITDA existing and $2.0 reflects $40 60.0% $1.6 new markets investments and $30 is expected 40.0% operational $20 to continue improvemen
Slide 14: Balance Sheet Turnaround
Balance Sheet Turnaround $8.0 $7.5 $7.0 $6.1 $6.0 $5.7 50% $6.0 $5.0 reduction in net $4.0 $3.7 debt $3.0$3.1 $3.2 $3.2 $2.8 while investing $3.0 in new facilities $2.0 $1.8 $1.6 (including three new fluoroscopy suites $1.0 in 2024) $0.0 Cash Debt Net Debt Adj EBITDA Q3/22 Q3/23 Q3/24 * Adj EBITDA T
Slide 15: Experienced Leadership
Experienced Leadership Joseph Walewicz Jeff Zygouras CPA, CA CEO CFO Joined Board of Directors Joined as Corporate Controller in 2020, became CEO in Sept. 2022 in 2019, promoted to CFO in 2021 25 years in biopharma, including Prior experience as Finance Manager Clementia Pharmaceuticals, at
Slide 16: Board of Directors: Highly Relevant Skills & Experience
Board of Directors: Highly Relevant Skills & Experience Currently serves as Executive Chairman of Crescita Therapeutics Inc. (TSX: CTX) Daniel Chicoine Previously served as Chairman and Co-CEO at Nuvo Research; also held executive roles at Magna Int’l and PowerCart Systems Director (Chair) Hol
Slide 17: Capitalization & Financial Data
Capitalization & Financial Data Financial Information Capital Structure Tight capital structure Common Shares Outstanding 56,400,893 44% institutional ownership Dilutive Instruments Majority held by close investors Warrants Outstanding(1) 5,316,111 Since joining NeuPath, CEO has Stock Option
Slide 18: Key Takeaways: Multiple Drivers of Shareholder Value
Key Takeaways: Multiple Drivers of Shareholder Value Successful turnaround – growing top line and adj EBITDA, improving margins and emerging profitability Multiple paths for growth Well-aligned with government policy and recent initiatives Demand for chronic pain treatment rising Significa
Slide 19: Thank you!
ee NeuPath ‘:.: Health Inc. & Thank you! : TSXV: NPTH
Slide 20: EBITDA Reconciliation of IFRS
EBITDA Reconciliation of IFRS EBITDA and Adjusted EBITDA EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA, as EBITDA, excluding stock-based
NeuPath Health — Investor Presentation (January 2025) on 6ix